Related Experiment Video

Updated: Jun 4, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Triptolide-induced cell cycle arrest and apoptosis in human renal cell carcinoma cells

Jingjie Li1, Wenbo Zhu, Tiandong Leng

  • 1Department of Pharmacology, Zhong-shan School of Medicine, Sun Yat-Sen University, Guangzhou, PR China.

Oncology Reports
|January 29, 2011
PubMed

Insights

Triptolide, a known anti-inflammatory drug, effectively triggers apoptosis in renal cell carcinoma (RCC) cells. It disrupts mitochondrial pathways and induces cell cycle arrest, offering potential for advanced RCC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is the most common kidney cancer.
  • Current treatments for advanced or refractory RCC remain inadequate.
  • Nephrectomy is effective for localized RCC but not for advanced stages.

Purpose of the Study:

  • To investigate the anti-cancer effects of triptolide on renal cell carcinoma (RCC) cells.
  • To elucidate the molecular mechanisms underlying triptolide-induced cell death in RCC.
  • To assess the potential of triptolide as a therapeutic agent for human RCC.

Main Methods:

  • Treatment of 786-0 and OS-RC-2 RCC cell lines with triptolide.
  • Analysis of apoptosis induction via the mitochondrial pathway.
  • Assessment of gene expression changes related to mitochondrial stabilization (Bcl-2, Bcl-XL).
  • Cell cycle analysis to determine effects on cell cycle phases (G0/G1, S, G2/M).
  • Evaluation of cell cycle checkpoint regulators (cyclin A, cyclin B, CDK1, CDK2, Rb).

Main Results:

  • Triptolide induced apoptosis in RCC cells through the mitochondrial pathway.
  • Triptolide reduced the expression of mitochondrial stabilizing genes Bcl-2 and Bcl-XL.
  • Triptolide caused cell cycle arrest, increasing the proportion of cells in the S phase.
  • This cell cycle arrest was linked to decreased expression of key cell cycle regulators.
  • Similar effects were observed in both 786-0 and OS-RC-2 RCC cell lines.

Conclusions:

  • Triptolide stimulates apoptosis in renal cell carcinoma by modulating mitochondrial pathways and inducing cell cycle arrest.
  • The drug influences the coordinated regulation of proliferation and apoptosis in RCC cells.
  • Triptolide shows promise as a potential therapeutic agent for treating human renal cell carcinoma, particularly advanced or refractory cases.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer09:13

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer

Published on: January 5, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...